Literature DB >> 3463821

Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases.

S L Aukerman, J E Price, I J Fidler.   

Abstract

To produce metastasis, malignant tumor cells must be able to complete a sequence of many steps that depend not only on tumor cell properties but also on ability of the tumor cells to interact effectively with host homeostatic mechanisms to avoid destruction. Therefore, it should be possible to isolate clonal populations non- or low metastatic. In a study of K-1735 clones introduced into normal syngeneic hosts, the reasons for the lack of or low ability of metastasis production did indeed differ among different clones. Some clones were identified that were low metastatic in syngeneic C3H/HeN mice because of antigenic characteristics. Others failed to give rise to metastases because they could not survive and grow once arrested in the lung parenchyma. These data suggested that the success of future studies dealing with genetic analysis of the metastatic phenotype could depend on the use of appropriate tumor cell populations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463821

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

1.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

Review 2.  AACR centennial series: the biology of cancer metastasis: historical perspective.

Authors:  James E Talmadge; Isaiah J Fidler
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

3.  Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma.

Authors:  Y Kitadai; L M Ellis; S L Tucker; G F Greene; C D Bucana; K R Cleary; Y Takahashi; E Tahara; I J Fidler
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 4.  Extracranial metastases of medulloblastoma in adults: literature review.

Authors:  S Rochkind; I Blatt; M Sadeh; Y Goldhammer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

5.  Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis.

Authors:  Linda Sequeira; Cara W Dubyk; Tracy A Riesenberger; Carlton R Cooper; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2008-05-07       Impact factor: 5.150

6.  Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones.

Authors:  K L van Golen; S Risin; A Staroselsky; D Berger; M A Tainsky; S Pathak; J E Price
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

Review 7.  Regulation of cancer metastasis by stress pathways.

Authors:  Keping Xie; Suyun Huang
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Individual rac GTPases mediate aspects of prostate cancer cell and bone marrow endothelial cell interactions.

Authors:  Moumita Chatterjee; Linda Sequeira; Mashariki Jenkins-Kabaila; Cara W Dubyk; Surabhi Pathak; Kenneth L van Golen
Journal:  J Signal Transduct       Date:  2011-06-27

9.  Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells.

Authors:  Y Hashimoto; N Shindo-Okada; M Tani; Y Nagamachi; K Takeuchi; T Shiroishi; H Toma; J Yokota
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

10.  Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells.

Authors:  K Xie; S Huang; Z Dong; S H Juang; M Gutman; Q W Xie; C Nathan; I J Fidler
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.